Oxygen Biotherapeutics' common stock approved for secondary listing on SIX Swiss Exchange

NewsGuard 100/100 Score
Jun 21 2010

Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that its common stock has been approved for secondary listing on the SIX Swiss Exchange in addition to its listing on the NASDAQ Capital Market. Bank am Bellevue of Zurich is acting as the company's listing agent.

"Broadening awareness of our company and making trading in our stock more accessible to our existing and potential shareholder bases were important considerations when we decided to list on the SIX," said Company Chairman and CEO Chris J. Stern. "While this listing took place by way of introduction with no new capital raised at this point, I believe it offers us access to a larger capital market, particularly in Europe."

Trading on the SIX for Oxygen Biotherapeutics' common stock is expected to begin on June 29, 2010. An announcement will be made signaling initiation of trading on the day it begins.

SOURCE Oxygen Biotherapeutics, Inc.

Posted in:

Tags: , , , , ,

Comments (0)

Suggested Reading

New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
How minerals influence women's fertility and menstrual health
A plant-based diet and its relationship with oxidative biomarkers in footballers
Red light therapy shown to significantly reduce blood sugar spikes, study finds
Study explores health benefits of selenium and zinc-enriched eggs
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
Missing gut microbes after antibiotics and a high-fat diet may be to blame for sugar-free candy and gum giving you gas
Beetroot juice outperforms nitrate supplements in boosting exercise performance

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study reveals inflammation's role in long COVID's lingering effects